ASCO 2024 | Promising survival outcomes in glioblastoma with autologous gamma-delta T cells
Mina Lobbous
• 1 Jun 2024
Mina Lobbous, MD, MPH, Case Western Reserve University, Cleveland, OH, highlights promising results in overall survival (OS) rates and safety from a Phase I study (NCT04165941) of INB-200, a gene-modified autologous (γδ) T cell therapy in patients with glioblastoma multiforme (GBM) receiving maintenance therapy with temozolomide. It is anticipated similar trends will be seen in an ongoing Phase II study. This interview took place during the 2024 American Society of Clinical Oncology (ASCO) Meeting in Chicago, IL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
